Russian-Belarusian Expert Council “New opportunities in the treatment of patients with multiple sclerosis” (October 1, 2023). Main conclusions of the first meeting-Reference-Cited by-同舟云学术

Russian-Belarusian Expert Council “New opportunities in the treatment of patients with multiple sclerosis” (October 1, 2023). Main conclusions of the first meeting

Published:2023-12-17 Issue:6 Volume:15 Page:146-150
ISSN:2310-1342
Container-title:Neurology, Neuropsychiatry, Psychosomatics
language:
Short-container-title:RJTAO

Author:

Boyko A. N.¹^ORCID,Vashchilin V. V.²^ORCID,Boyko O. V.³^ORCID,Bunyak A. G.²^ORCID,Kasatkin D. S.⁴^ORCID,Korobko D. S.⁵^ORCID,Kulikova S. I.²^ORCID,Mazgo N. V.⁶^ORCID,Makovskaya N. V.⁷^ORCID,Sivertseva S. A.⁸^ORCID,Smagina I. V.⁹^ORCID,Chernukha T. N.²^ORCID

Affiliation:

1. N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia; Institute of Clinical Neurology and Department of Neuroimmunology, Federal Center of Brain and Neurotechnologies, FMBA of Russia

2. Republican Research and Clinical Center of Neurology and Neurosurgery, Ministry of Health of Belarus

3. Institute of Clinical Neurology and Department of Neuroimmunology, Federal Center of Brain and Neurotechnologies, FMBA of Russia

4. Yaroslavl State Medical University, Ministry of Health of Russia

5. Regional Center of Multiple Sclerosis and other Autoimmune Diseases of Nervous system, Novosibirsk State Regional Clinical Hospital; Novosibirsk State Medical University, Ministry of Health of Russia

6. Minsk Regional Clinical Hospital

7. Minsk Clinical Consultative and Diagnostic Center

8. LLC “Neftyanik” Primary Healthcare Unit, Tyumen Regional Center for Multiple Sclerosis; Kirov State Medical University, Ministry of Health of Russia; Ural State Medical University, Ministry of Health of Russia

9. Altai State Medical University, Ministry of Health of Russia

Abstract

A joint conclusion of the Russian-Belarusian Expert Council “New opportunities in the treatment of patients with multiple sclerosis” on the organization of medical care, diagnosis and treatment of multiple sclerosis (MS) and other autoimmune diseases is presented. 12 neurologists from different medical institutions in Russia and Belarus took part in the work of the Council. In the conclusions of the Council, special attention was paid to two new Russian original drugs, modifying the course of MS. The place of these drugs in the healthcare system of these countries was determined. Sampeginterferon beta-1a itself is an effective and safe drug of first choice (first-line treatment) for relapsing remitting MS. Divozilimab is a highly effective and safe second-line treatment indicated for rapidly progressive and highly active MS, even when substituted for a firstor second-line treatment in relapsing remitting and secondary progressive (with exacerbations) MS. The experts emphasized how promising the use of these drugs is in the complex treatment of MS.

Publisher

IMA Press, LLC

Subject

Psychiatry and Mental health,Neurology (clinical),Clinical Psychology

Reference10 articles.

1. Kulikov AYu, Tishchenko DG. Economic burden of multiple sclerosis in the Republic of Belarus. Farmakoekonomika: teoriya i praktika. 2015;3(2):96-101 (In Russ.).

2. Gusev EI, Boyko AN. Rasseyannyy skleroz. Nauchno-prakticheskoye rukovodstvo [Multiple sclerosis. Scientific and practical guide]: In 2 volumes. Moscow: ROOI “Human Health”; 2020. Vol. 1. 608 p. ISBN 978-5-6044140-2-6; Vol. 2. 566 p. ISBN 978-5-6044140-5-7 (In Russ.)].

3. Smirnov VS, Galinovskaya NV. Clinical characteristics of patients with multiple sclerosis according to the registry of the Gomel region. Mediko-biologicheskie problemy zhiznedeyatel'nosti = Medical and Biological Problems of Life Activity. 2022;(1):124-34 (In Russ.).

4. Wiendl H, Gold R, Berger T, et al; 'Multiple Sclerosis Therapy Consensus Group' (MSTCG). Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper). Ther Adv Neurol Disord. 2021 Aug 18;14:17562864211039648. doi: 10.1177/17562864211039648

5. Boyko AN, Bakhtiyarova KZ, Dudin VA, et al. The new pegylated interferon beta-1a (sampeginterferon beta-1a, BCD-054) in the treatment of remitting multiple sclerosis. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2019;119(10-2):100-9. doi: 10.17116/jnevro2019119102100 (In Russ.)].